SeekingAlpha · Sep 11, 2026
Ironwood: Medicare Is Not The Problem I Thought It Was
Ironwood now expects 2026 LINZESS net sales of $1.15 billion to $1.20 billion and adjusted EBITDA above $310 million. Read why IRWD stock is a buy.
IR
NASDAQ · IRWD
Ironwood Pharmaceuticals, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$3.63
Down-$0.02 (-0.55%)
Updated Oct 7, 2026, 7:49 AM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 598.66M
- P/E ratio
- 7.07
- Dividend yield
- 0.00%
- 52-week range
- $3.02 – $4.88
- Volume
- 1.87M
- Avg. volume
- 2.12M
Price performance · IRWD
IRWD price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
IRWD closed at $3.63 after 21 trading sessions, down 12.95% for the selected period.
- Last close
- $3.63
- Period change
- -12.95%
- Period low
- $3.63
- Period high
- $4.53
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $3.64 | $3.6791 | $3.595 | $3.63 | 1.87M |
| Oct 5, 2026 | $3.59 | $3.67 | $3.55 | $3.65 | 2.23M |
| Oct 2, 2026 | $3.74 | $3.796 | $3.58 | $3.64 | 2.7M |
| Oct 1, 2026 | $3.95 | $3.97 | $3.735 | $3.76 | 2.64M |
| Sep 30, 2026 | $4.16 | $4.17 | $3.96 | $3.97 | 1.66M |
| Sep 29, 2026 | $4.12 | $4.17 | $4.08 | $4.16 | 1.23M |
| Sep 28, 2026 | $4.09 | $4.17 | $4.04 | $4.12 | 1.96M |
| Sep 25, 2026 | $4.22 | $4.25 | $4.10 | $4.13 | 1.32M |
| Sep 24, 2026 | $4.23 | $4.2598 | $4.05 | $4.19 | 1.75M |
| Sep 23, 2026 | $4.50 | $4.536 | $4.25 | $4.27 | 1.66M |
| Sep 22, 2026 | $4.46 | $4.59 | $4.395 | $4.525 | 3.43M |
| Sep 21, 2026 | $4.39 | $4.595 | $4.30 | $4.41 | 2.41M |
| Sep 18, 2026 | $4.20 | $4.385 | $4.17 | $4.36 | 7.69M |
| Sep 17, 2026 | $4.27 | $4.48 | $4.20 | $4.23 | 3.49M |
| Sep 16, 2026 | $4.07 | $4.24 | $4.06 | $4.17 | 1.31M |
| Sep 15, 2026 | $4.18 | $4.18 | $4.045 | $4.06 | 1.12M |
| Sep 14, 2026 | $4.10 | $4.185 | $4.082 | $4.17 | 1.25M |
| Sep 11, 2026 | $4.03 | $4.105 | $3.94 | $4.08 | 1.25M |
| Sep 10, 2026 | $4.03 | $4.05 | $3.94 | $3.97 | 1.17M |
| Sep 9, 2026 | $4.14 | $4.16 | $4.035 | $4.07 | 1.48M |
| Sep 8, 2026 | $4.25 | $4.27 | $4.075 | $4.17 | 2.28M |
Latest IRWD news
The latest Smart Investors Daily articles mentioning IRWD.
Stock researchCompany · Overview
Company
Market Activity
Research & News
IRWD research
Overview
Company profile and research snapshot.
Company profile
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $3.80
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 26, 2026 | Citizens | Market Outperform | — |
| Jan 5, 2026 | Wells Fargo | Equal-Weight | — |
| Jan 5, 2026 | Citizens | Market Outperform | — |
| Nov 11, 2025 | Wells Fargo | Equal-Weight | — |
| Apr 15, 2025 | Wells Fargo | Equal-Weight | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 3, 2026
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
BOSTON, September 03, 2026--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10th at 10:15 a.m. ET.
SeekingAlpha · Aug 26, 2026
Ironwood Pharmaceuticals: High Dependence On Its Next Trial
Ironwood Pharmaceuticals is a small-cap GI-focused biotech with strong LINZESS sales but looming patent expiry by 2029â2030. Learn more about IRWD stock here.
ChartMill · Aug 26, 2026
Ironwood Pharmaceuticals (NASDAQ:IRWD) Highlights Minervini Trend Template and High Growth Momentum
Ironwood Pharmaceuticals (IRWD) passes Mark Minervini’s trend template and high-growth momentum screen, with strong uptrend, rising averages, and accelerating earnings. A potential growth stock setup, though risks remain.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
